Asthma exacerbations declined during the COVID-19 pandemic, with up to a 90% drop in certain pediatric populations, research shows.

However, findings of multiple studies suggest that patients with asthma likely did not forego needed care – because asthma exacerbations actually decreased during the early days of the COVID-19 pandemic.

One such study, the PREPARE trial (Patient Empowered Strategy to Reduce Asthma Morbidity in Highly Impacted Populations – PeRson EmPowered Asthma RElief; Identifier: NCT02995733), investigated changes in asthma exacerbation rates among African American and Hispanic/Latinx adults (n = 1178) from 19 clinical practices across the US. The PREPARE study analyzed monthly patient self-reports, collected from November 2018 through March 2020, using the Asthma Exacerbation Questionnaire.

In an article published in the July 2021 Journal of Allergy and Clinical Immunology: In Practice, PREPARE investigators reported a 41% relative reduction in asthma exacerbations during the first and second quarters of 2020 vs those same quarters during previous years of the study. Notably, greater reductions were observed in Hispanic/Latinx patients (50%) compared to African American/Black patients (27%) and in individuals who worked outside of the home (65%) before the pandemic compared to those working at home (23%).

Get the full story at

Asthma Exacerbations Declined

Go To Source For Respiratory Therapy Coverage

RT delivers in-depth coverage of the clinical, regulatory, and technology landscape for respiratory therapy—and reaches more than 28,000 key decision-makers and influencers. As one of healthcare’s most important data companies, we facilitate the rapid adoption of medical devices and practice management tools into the industry.